<?xml version="1.0" encoding="utf-8"?><rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom"><channel><title>Genitourinary Malignancy Virtual Journal Club</title><link>http://primeoncology.org/virtualjournalclub_all</link><description></description><language>EN-US</language><generator>TandemServer.org | Tandem Server CMS | Version: 2010.05.01</generator><atom:link href="http://primeoncology.org/Feed.aspx?ControlId=1995" rel="self" type="application/rss+xml" /><item><title>Pazopanib in Locally Advanced or Metastatic Renal Cell Carcinoma: Results of a Randomized Phase III Trial</title><link>http://primeoncology.org/article.aspx?ArticleId=328</link><guid isPermaLink="true">http://primeoncology.org/article.aspx?ArticleId=328</guid><description>&lt;strong&gt;Cora Sternberg, MD, FACP&lt;/strong&gt;, is interviewed
regarding the published results of VEG105192, a randomized double-blind, placebo-controlled, trial evaluating treatment with pazopanib in patients with advanced and/or metastatic renal cell carcinoma who had progressed on one prior cytokine-based systemic therapy and how these results may affect clinical practice.
&lt;a href="http://primeoncology.org/VJC_GU_sternberg"&gt;View Webcast&lt;/a&gt;&lt;br /&gt;
&lt;span style="font-size: 8pt;"&gt;This Webcast is available from July 2010 to July 2011.
&lt;/span&gt;</description><pubDate>2010-07-13T12:28:59</pubDate></item></channel></rss>
